Patent Daily RSS
Twitter Guna
- Access the Bayer’s appeal - bit.ly/Lj9RMP 6 days ago
- Bayer seeks to stay the operation of the CL order - bit.ly/JBAlIS 6 days ago
- USPTO Offers Patent Applicants Option to Supplement Disclosure of Prior Art After Paying Issue Fee - bit.ly/Ju5BYd 1 week ago
- Piramal Healthcare to buy US firm to boost R&D - bit.ly/MiVA1V 1 week ago
- Financial challenges, novel drug devpt pressures to hamper India’s R&D growth: Expert - bit.ly/JHsWnw 1 week ago
- Biotech body criticises Bayer on cancer drug - bit.ly/J5DEpF 1 week ago
- India drugs inquiry could prompt new U.S. scrutiny - reut.rs/JDVT5y 1 week ago
- Cipla breached patent rights by slashing cancer drug price: Bayer - bit.ly/JyCBys 2 weeks ago
- No pharma application pending for compulsory licence: Govt - bit.ly/K3OUQy 2 weeks ago
- India’s patent protection regime to be key issue in talks with US - bit.ly/Jfhluh 2 weeks ago
Daily Archives: 30/06/2011
India: Varenacline Patent revoked
Varenaciline is marketed by Pfizer world wide as Chandix or Champix. Varenaciline is marketed as tartarate salt form, this salt form is protected by US patent 6890927 and its indian equivalent is 204091 (863/MUMNP/2003). This ’091 patent is opposed by Dr … Continue reading
Posted in Patent case
Tagged 204091, 863/MUMNP/2003, Champix, Chandix, Dr Reddy's, pfizer
Leave a comment
